ImmuneOnco takes a second project pivotal
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
Instil’s bispecific dream is over
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
One ricochet of the ivonescimab bullet
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
